Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150003/S113

SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System SYNERGY XD Everolimus-Eluting Platinum Chromium Coron

BOSTON SCIENTIFIC CORPORATION · Decision date Aug 21, 2026

FDA DECISIONP150003/S113

What did the FDA decide?

FDA records P150003/S113 as a supplement to PMA P150003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 21, 2026.

FDA approval order statement

implementation of parametric release and an alternate biological indicator at the sterilization sites
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Aug 21, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P150003/S113
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
OK30
Decision date
Aug 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150003/S110 · Related supplement

    SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System

  2. P150003/S113 received

    Application receipt date recorded by FDA.

  3. P150003/S113 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P150003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150003

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 29, 2025FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records